» Articles » PMID: 1995891

Configuration and Preferential Solid-state Conformations of Perindoprilat (S-9780). Comparison with the Crystal Structures of Other ACE Inhibitors and Conclusions Related to Structure-activity Relationships

Overview
Journal J Med Chem
Specialty Chemistry
Date 1991 Feb 1
PMID 1995891
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The conformation of perindoprilat, an antihypertensive drug, is studied in the solid state by X-ray analysis. The resolution of its structure reveals important analogies between its observed conformation and that of several ACE inhibitors of the same family. This comparison points out a constant relative orientation of the functional groups, regardless of the molecular environment. This angular constancy appears to us as not being accidental and is a good argument for the spatial design of the ACE binding site. Although ACE is a carboxydipeptidase, the binding site may not contain two but one unique hydrophobic pocket receiving the C-terminal end of the inhibitors.

Citing Articles

Cobalt-catalyzed conformationally restricted alkylarylation enables divergent access to Csp-rich N-heterocycles.

Chen K, Lin J, Jing J, Wang J, Hu J, Yi H Chem Sci. 2024; .

PMID: 39297003 PMC: 11406614. DOI: 10.1039/d4sc04056b.


The Development and Validation of a Stability-Indicating UHPLC-DAD Method for Determination of Perindopril l-Arginine in Bulk Substance and Pharmaceutical Dosage Form.

Paczkowska M, Zalewski P, Garbacki P, Talaczynska A, Krause A, Cielecka-Piontek J Chromatographia. 2014; 77(21-22):1497-1501.

PMID: 25400289 PMC: 4224746. DOI: 10.1007/s10337-014-2724-7.


Sustained release of prindopril erbumine from its chitosan-coated magnetic nanoparticles for biomedical applications.

Dorniani D, Hussein M, Kura A, Fakurazi S, Shaari A, Ahmad Z Int J Mol Sci. 2013; 14(12):23639-53.

PMID: 24300098 PMC: 3876068. DOI: 10.3390/ijms141223639.


Comparative study of Mg/Al- and Zn/Al-layered double hydroxide-perindopril erbumine nanocomposites for inhibition of angiotensin-converting enzyme.

Hussein Al Ali S, Al-Qubaisi M, Hussein M, Ismail M, Zainal Z, Hakim M Int J Nanomedicine. 2012; 7:4251-62.

PMID: 22904631 PMC: 3418079. DOI: 10.2147/IJN.S32267.


Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite.

Hussein Al Ali S, Al-Qubaisi M, Hussein M, Ismail M, Zainal Z, Hakim M Int J Nanomedicine. 2012; 7:2129-41.

PMID: 22619549 PMC: 3356206. DOI: 10.2147/IJN.S30461.